Ligand Pharmaceuticals amends credit agreement to permit $700M convertible notes issuance.

Ligand Pharmaceuticals entered into a fourth amendment to its credit agreement with Citibank as administrative agent, consenting to the issuance of up to $700 million in unsecured convertible notes subject to leverage ratio compliance. The amendment provides financing flexibility while maintaining debt covenants under the existing October 2023 credit facility.